DAY ONE BIOPHARMACEUTICALS I's ticker is DAWN and the CUSIP is 23954D109. A total of 91 filers reported holding DAY ONE BIOPHARMACEUTICALS I in Q2 2022. The put-call ratio across all filers is 0.35 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,582,802 | +2.8% | 1,269,992 | 0.0% | 0.34% | +5.9% |
| Q2 2023 | $15,163,704 | -26.9% | 1,269,992 | +31.7% | 0.32% | -24.5% |
| Q4 2022 | $20,745,990 | +0.4% | 964,033 | -6.6% | 0.43% | +4.4% |
| Q3 2022 | $20,671,000 | -67.1% | 1,032,000 | -70.6% | 0.41% | -68.3% |
| Q2 2022 | $62,867,000 | +203.7% | 3,512,123 | +68.3% | 1.30% | +180.1% |
| Q1 2022 | $20,698,000 | -44.2% | 2,086,449 | -5.3% | 0.46% | -40.5% |
| Q4 2021 | $37,113,000 | -8.6% | 2,202,533 | +28.7% | 0.78% | -1.8% |
| Q3 2021 | $40,596,000 | +117.7% | 1,710,730 | +108.9% | 0.79% | +139.3% |
| Q2 2021 | $18,648,000 | – | 818,980 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Canaan Partners XI LLC | 6,964,301 | $139,495,000 | 56.26% |
| PATHWAY CAPITAL MANAGEMENT, LP | 403,127 | $8,075,000 | 25.88% |
| Atlas Venture Life Science Advisors, LLC | 8,169,171 | $163,628,000 | 18.06% |
| RA Capital Management | 7,040,622 | $141,024,000 | 3.01% |
| COMMODORE CAPITAL LP | 739,661 | $14,815,000 | 2.38% |
| Nicholas Investment Partners, LP | 757,407 | $15,171,000 | 1.41% |
| Boxer Capital, LLC | 1,189,943 | $23,835,000 | 1.34% |
| Parkman Healthcare Partners LLC | 212,191 | $4,250,000 | 1.21% |
| TANG CAPITAL MANAGEMENT LLC | 400,000 | $8,012,000 | 0.98% |
| Samsara BioCapital, LLC | 196,425 | $3,934,000 | 0.92% |